Compare SONO & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONO | CDNA |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2018 | 2007 |
| Metric | SONO | CDNA |
|---|---|---|
| Price | $15.81 | $48.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $19.67 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.77 | ★ 2.13 |
| Revenue | ★ $1,443,276,000.00 | $48,324,000.00 |
| Revenue This Year | $5.04 | $16.01 |
| Revenue Next Year | $6.53 | $11.31 |
| P/E Ratio | ★ $20.84 | $22.06 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $12.44 | $12.37 |
| 52 Week High | $19.82 | $49.76 |
| Indicator | SONO | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 71.19 |
| Support Level | $15.77 | $16.20 |
| Resistance Level | $17.26 | $49.76 |
| Average True Range (ATR) | 0.67 | 1.85 |
| MACD | -0.02 | -0.39 |
| Stochastic Oscillator | 42.65 | 93.01 |
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.